Siren Biotechnology blends two revolutionary therapeutic technologies into one for a novel approach to treating cancer.AAV gene therapy and cytokine immunotherapy are two revolutionary treatment approaches that Siren Biotechnology has combined into a single, redesigned modality. This approach overcomes significant obstacles and entirely transforms how tumor cells are eliminated and anti-tumor immunity is stimulated.
Alife develops artificial intelligence tools to assist physicians in increasing a patient's chances of pregnancy success. The company has a mission of helping people have healthy children and connects fertility specialists to patients to assists with IVF. Alife Health was founded in 2020 by Paxton Maeder-York and is headquartered in San Francisco, California, United States.
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of true drug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas.
Nomic is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. They are building the nELISA, a next-generation ELISA platform for measuring proteins at scale and at high throughput. They offer scientists protein profiling solutions to empower them to decide the scope and scale of their experiments.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
A-Alpha Bio is a provider of cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio utilizes its proprietary AlphaSeq technology to map protein-protein interactions at a high scale and resolution. This technology can identify and quantify interactions between thousands of protein pairs simultaneously. By providing detailed maps of protein interactions, A-Alpha Bio aids in the identification of potential drug targets and the understanding of disease mechanisms. This can significantly streamline the process of discovering new therapeutics. A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from living organisms. By developing a comprehensive database of chemical biodiversity, Enveda aims to accelerate the discovery of new medicines.
Strateos operates a robotic cloud laboratory that automates chemistry, biology, and tissue analysis to enhance drug discovery processes. By integrating advanced robotics, control systems, and sophisticated imaging and analytics software, Strateos allows pharmaceutical companies to discover new drug candidates more efficiently. The company emerged from a merger between Transcriptic, known for its pioneering robotic cloud laboratory platform, and 3Scan, which specialized in using automation and machine learning to analyze tissue samples. This combination enables Strateos to provide a comprehensive suite of technologies designed to streamline the drug discovery and early development phases. By transforming life science methodologies into data-driven processes, Strateos aims to create a more efficient and cost-effective approach to scientific research, positioning itself as a valuable partner to biotechnology firms seeking to innovate in the field.
Alife develops artificial intelligence tools to assist physicians in increasing a patient's chances of pregnancy success. The company has a mission of helping people have healthy children and connects fertility specialists to patients to assists with IVF. Alife Health was founded in 2020 by Paxton Maeder-York and is headquartered in San Francisco, California, United States.
Benchling is the modern software platform purpose-built for life science R&D. Hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering depend on our suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&D decisions.
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of true drug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas.
Senti Biosciences is a biotechnology company focused on synthetic biology and gene circuit engineering for therapeutic applications. Senti Bio utilizes a synthetic biology platform named Gene Circuits to develop therapies that offer improved precision and control. These circuits are engineered to selectively eliminate cancer cells while sparing healthy ones, enhancing specificity for target cells, and regulating drug expression post-administration.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Thrive Earlier Detection Corp. is a healthcare company that specializes in developing advanced blood testing technologies for early cancer detection. Its flagship product, CancerSEEK, is a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma, allowing for the identification of various cancers at their nascent stages, often before symptoms manifest. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate cancer screening into standard medical practice. The company leverages real-world data and machine learning to enhance the accuracy of cancer detection, facilitate follow-up testing, and streamline the transition to oncological care. Thrive operates as a subsidiary of Exact Sciences Corporation and has received investments from notable firms including Third Rock Ventures and Section 32.
Benchling is the modern software platform purpose-built for life science R&D. Hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering depend on our suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&D decisions.
Cajal Neuroscience is a biotechnology company integrating human genetics, functional genomics, and advanced microscopy to discover novel targets and therapeutics for neurodegeneration. The company combines a suite of state-of-the-art approaches and technologies, including integrative human genetics and multi-omics, high-throughput functional genomics, and advanced microscopy, to accelerate neurodegeneration target and drug discovery.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits. Variant Bio was founded in 2018 and headquartered in Seattle, Washington.
Strateos operates a robotic cloud laboratory that automates chemistry, biology, and tissue analysis to enhance drug discovery processes. By integrating advanced robotics, control systems, and sophisticated imaging and analytics software, Strateos allows pharmaceutical companies to discover new drug candidates more efficiently. The company emerged from a merger between Transcriptic, known for its pioneering robotic cloud laboratory platform, and 3Scan, which specialized in using automation and machine learning to analyze tissue samples. This combination enables Strateos to provide a comprehensive suite of technologies designed to streamline the drug discovery and early development phases. By transforming life science methodologies into data-driven processes, Strateos aims to create a more efficient and cost-effective approach to scientific research, positioning itself as a valuable partner to biotechnology firms seeking to innovate in the field.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare. It is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the 3 Rs, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies to academia and novel therapeutic labs. Vium's digital platform provides physiological biomarkers that enable better decisions on which compounds should be advanced to the clinic. The company's platform Digital Vivariumand Vium Cloud is the gold-standard in vivo platform combining computer vision, artificial intelligence, machine learning, and sensor technology to non-invasively collect and derive insights from digital biomarkers. The platform continuously captures physiological metrics and behaviors non-invasively, providing more sensitive and accurate data collection, leading to more replicable studies. Vium was founded in 2013 and is headquartered in San Mateo, California, United States.
Senti Biosciences is a biotechnology company focused on synthetic biology and gene circuit engineering for therapeutic applications. Senti Bio utilizes a synthetic biology platform named Gene Circuits to develop therapies that offer improved precision and control. These circuits are engineered to selectively eliminate cancer cells while sparing healthy ones, enhancing specificity for target cells, and regulating drug expression post-administration.
Octant Bio is a developer of synthetic technology used to improve health and treat disease. Its technology uses synthetic biology, genome engineering, next-generation sequencing, and computational tools to simultaneously measure the activity of thousands of receptor pathways in human cells that enable scientists to apply machine learning methods to engineer small molecules that interact with multiple receptors and unlock a new potential to treat complex diseases.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare. It is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the 3 Rs, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies to academia and novel therapeutic labs. Vium's digital platform provides physiological biomarkers that enable better decisions on which compounds should be advanced to the clinic. The company's platform Digital Vivariumand Vium Cloud is the gold-standard in vivo platform combining computer vision, artificial intelligence, machine learning, and sensor technology to non-invasively collect and derive insights from digital biomarkers. The platform continuously captures physiological metrics and behaviors non-invasively, providing more sensitive and accurate data collection, leading to more replicable studies. Vium was founded in 2013 and is headquartered in San Mateo, California, United States.
Capella Bioscience engages in the discovery and development of monoclonal antibodies (mAbs). It focuses on the employment of proprietary technologies to discover, develop, and commercialize medicines based on mAbs therapeutics for oncology, autoimmune, and other diseases independently, as well in collaboration with biotechnology and academic partners
Strateos operates a robotic cloud laboratory that automates chemistry, biology, and tissue analysis to enhance drug discovery processes. By integrating advanced robotics, control systems, and sophisticated imaging and analytics software, Strateos allows pharmaceutical companies to discover new drug candidates more efficiently. The company emerged from a merger between Transcriptic, known for its pioneering robotic cloud laboratory platform, and 3Scan, which specialized in using automation and machine learning to analyze tissue samples. This combination enables Strateos to provide a comprehensive suite of technologies designed to streamline the drug discovery and early development phases. By transforming life science methodologies into data-driven processes, Strateos aims to create a more efficient and cost-effective approach to scientific research, positioning itself as a valuable partner to biotechnology firms seeking to innovate in the field.
Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare. It is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the 3 Rs, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies to academia and novel therapeutic labs. Vium's digital platform provides physiological biomarkers that enable better decisions on which compounds should be advanced to the clinic. The company's platform Digital Vivariumand Vium Cloud is the gold-standard in vivo platform combining computer vision, artificial intelligence, machine learning, and sensor technology to non-invasively collect and derive insights from digital biomarkers. The platform continuously captures physiological metrics and behaviors non-invasively, providing more sensitive and accurate data collection, leading to more replicable studies. Vium was founded in 2013 and is headquartered in San Mateo, California, United States.
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Magen BioSciences is a biotechnology company based in Waltham, Massachusetts, focused on developing pharmaceutical products aimed at enhancing human skin health. Utilizing a science-driven approach, the company leverages its comprehensive understanding of both normal and diseased skin biology to create solutions that improve the health and appearance of the skin.